KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
Latest Information Update: 10 May 2024
At a glance
- Drugs KB 407 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms CORAL-1
- Sponsors Krystal Biotech
- 06 May 2024 According to Krystal Biotech media release, the company has completed dosing in Cohort 2 in the trial. The Company intends to initiate the third and final cohort in 2Q 2024.
- 26 Feb 2024 According to Krystal Biotech media release, the company initiated dosing in Cohort 2 of this study in January 2024.
- 25 Jul 2023 Planned number of patients changed from 20 to 12.